Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-FAST: Blood-First Assay Screening Trial in Advanced or Metastatic NSCLC (Japan)
jRCT2080223780Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised trial of atezolizumab and entrectinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Jan 2018; status: completed.
02
Drugs
atezolizumabentrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223780.